BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24316627)

  • 1. First-in-class guanylate cyclase stimulator approved for PAH.
    Guha M
    Nat Biotechnol; 2013 Dec; 31(12):1064. PubMed ID: 24316627
    [No Abstract]   [Full Text] [Related]  

  • 2. Riociguat approved for pulmonary hypertension.
    Traynor K
    Am J Health Syst Pharm; 2013 Nov; 70(22):1960. PubMed ID: 24173000
    [No Abstract]   [Full Text] [Related]  

  • 3. Riociguat: first global approval.
    Conole D; Scott LJ
    Drugs; 2013 Nov; 73(17):1967-75. PubMed ID: 24218053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
    Leuchte HH; Behr J; Ewert R; Ghofrani HA; GrĂ¼nig E; Halank M; Held M; Klose H; Rosenkranz S; Schermuly RT; Wilkens H; Hoeper MM
    Pneumologie; 2015 Mar; 69(3):135-43. PubMed ID: 25750094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Hill NS; Rahaghi FF; Sood N; Frey R; Ghofrani HA
    Respir Med; 2017 Aug; 129():124-129. PubMed ID: 28732819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Mielniczuk LM; Swiston JR; Mehta S
    Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Riociguat - a stimulator of soluble guanylate cyclase: a new mode of action helps patients with pulmonary hypertension].
    Kreutzkamp B
    Med Monatsschr Pharm; 2013 Dec; 36(12):442-7. PubMed ID: 24450268
    [No Abstract]   [Full Text] [Related]  

  • 10. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Lian TY; Jiang X; Jing ZC
    Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
    Kim NH
    Eur Respir Rev; 2010 Mar; 19(115):68-71. PubMed ID: 20956169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Belik J
    Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecule of the month. Riociguat.
    Drug News Perspect; 2009 Apr; 22(3):167. PubMed ID: 19440559
    [No Abstract]   [Full Text] [Related]  

  • 14. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy.
    Ghofrani HA; Grimminger F
    Eur Respir Rev; 2009 Mar; 18(111):35-41. PubMed ID: 20956121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riociguat for the treatment of pulmonary hypertension.
    Meis T; Behr J
    Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary vascular reserve during experimental pulmonary embolism: effects of a soluble guanylate cyclase stimulator, BAY 41-8543.
    Watts JA; Gellar MA; Fulkerson MB; Kline JA
    Crit Care Med; 2011 Dec; 39(12):2700-4. PubMed ID: 21705882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
    Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
    Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
    DeSouza SA; Preston IR
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is distal chronic thromboembolic pulmonary hypertension treatable with PAH targeted drugs?
    Cannon JE; Pepke-Zaba J
    Semin Respir Crit Care Med; 2013 Oct; 34(5):620-6. PubMed ID: 24037629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riociguat: a novel new drug for treatment of pulmonary hypertension.
    Makowski CT; Rissmiller RW; Bullington WM
    Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.